Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 9/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 7/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 4/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 2/20 | 1.00 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 1.00 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 1.00 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 1.00 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 1.00 |
| ▸ | JAK2 | O60674 | 1/20 | 0.65 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.57 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8077840 | 0.89 | HDAC1 (0.80) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| SCHEMBL4262028 | 0.88 | HDAC1 (0.77) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| SCHEMBL1065275 | 0.88 | HDAC1 (0.77) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| SCHEMBL4262022 | 0.88 | HDAC1 (0.77) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| SCHEMBL2107670 | 0.87 | HDAC1 (0.82) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| SCHEMBL2828860 | 0.85 | HDAC1 (0.74) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| SCHEMBL2830015 | 0.85 | HDAC1 (0.74) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| SCHEMBL5031015 | 0.84 | HDAC1 (0.70) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| SCHEMBL5224545 | 0.83 | HDAC1 (0.70) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| SCHEMBL3558274 | 0.82 | HDAC1 (0.71) | HDAC1HDAC3HDAC2HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1495002-B1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2012-09-05 | — | — | EP | claimed |
| EP-1495002-B1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2012-09-05 | — | — | EP | disclosed |
| US-8247562-B2 | Benzamide derivatives useful as histone deacetylase inhibitors | ASTRAZENECA AB (SE) | 2012-08-21 | — | — | US | disclosed |
| US-7868204-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2011-01-11 | — | — | US | disclosed |
| US-7868204-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2011-01-11 | — | — | US | disclosed |
| US-7868204-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2011-01-11 | — | — | US | disclosed |
| US-20100331329-A1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-30 | — | — | US | disclosed |
| US-7838520-B2 | Inhibitors of histone deacetylase | METHYLGENE, INC. (CA) | 2010-11-23 | — | — | US | disclosed |
| US-7838520-B2 | Inhibitors of histone deacetylase | METHYLGENE, INC. (CA) | 2010-11-23 | — | — | US | disclosed |
| US-7838520-B2 | Inhibitors of histone deacetylase | METHYLGENE, INC. (CA) | 2010-11-23 | — | — | US | disclosed |
| US-20050171103-A1 | Benzamide derivatives useful as histone deacetylase inhibitors | ASTRAZENECA AB (SE) | 2005-08-04 | — | — | US | disclosed |
| CN-1642915-A | Benzamide derivatives useful as inhibitors of histone deacetylase | ASTRAZENECA AB (SE) | 2005-07-20 | — | — | CN | disclosed |
| US-6897220-B2 | Inhibitors of histone deacetylase | METHYLGENE, INC. (CA) | 2005-05-24 | — | — | US | disclosed |
| EP-1495002-A1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | Astrazeneca AB (SE) | 2005-01-12 | — | — | EP | disclosed |
| WO-2004069823-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2004-08-19 | — | — | WO | disclosed |
| WO-2004069823-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2004-08-19 | — | — | WO | disclosed |
| US-20040142953-A1 | Inhibitors of histone deacetylase | METHYLGENE, INC. | 2004-07-22 | — | — | US | disclosed |
| US-20040106599-A1 | Inhibitors of histone deacetylase | 92229129 QUEBEC INC. (CA) | 2004-06-03 | — | — | US | disclosed |
| WO-2003087057-A1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2003-10-23 | — | — | WO | disclosed |
| WO-2003024448-A2 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106599-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC5, HDAC3 | HDAC1 1/4885HDAC3 3/4885HDAC2 5/4885 |
| US-20050171103-A1 | Benzamide derivatives useful as histone deacetylase inhibitors | HDAC3, HDAC1, HDAC4 | HDAC1 2/4885HDAC3 1/4885HDAC2 5/4885 |
| US-20040142953-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC5, HDAC3 | HDAC1 1/4885HDAC3 3/4885HDAC2 5/4885 |
| US-20100331329-A1 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS | HDAC3, HDAC1, HDAC4 | HDAC1 2/4885HDAC3 1/4885HDAC2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.